CompletedPhase 4NCT02180763

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Octapharma
Principal Investigator
Boris Bienvenu, MD
Universtiy Hospital of Caen
Intervention
Gammanorm(biological)
Enrollment
31 enrolled
Eligibility
18 years · All sexes
Timeline
20142017

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02180763 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency

← Back to all trials